Showing 3 posts of 3 posts found.


Idorsia reveals it is working with Neurocrine on new epilepsy drug deal

January 10, 2020
Medical Communications FDA, Idorsia, Neurocrine, drugs, epilepsy, pharma

Idorsia revealed its 2019 deal for its investigational epilepsy medicine was with Neurocrine Biosciences, and it is potentially worth more …

J&J opts in on Idorsia’s candidate for $230m

December 4, 2017
Sales and Marketing Idorsia, Johnson & Johnson, biotech, drugs, pharma, pharmaceutical

As part of Johnson & Johnson’s acquisition of Actelion, it was able to secure a number of ties with the …


Actelion spin-off hit by blow shortly before buyout

June 9, 2017
Medical Communications, Research and Development Actelion, Idorsia, J&J, JJ

Idorsia, the spin-off R&D company of Actelion, has been hit a blow even before it has left the ground. The …

Latest content